iBio, Inc. (IBIO)


+0.01 (+5.00%)
Symbol IBIO
Price $0.2604
Beta -4.648
Volume Avg. 3.05M
Market Cap 56.810M
Shares () -
52 Week Range 0.22-1.46
1y Target Est -
DCF Unlevered IBIO DCF ->
DCF Levered IBIO LDCF ->
ROE -12.95% Sell
ROA -10.64% Sell
Operating Margin -
Debt / Equity 45.34% Neutral
P/E -
P/B 0.72 Buy


Consensus EPS

Upgrades & Downgrades

Latest IBIO news

Mr. Thomas Isett
American Stock Exchange

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.